Fecal microbiota transplantation as an early therapeutic option in treatment refractory Clostridioides difficile infection

Journal of Gastroenterology and HepatologyEarly View Letter to the Editor Fecal microbiota transplantation as an early therapeutic option in treatment refractory Clostridioides difficile infection OC Buldukoglu, Corresponding Author OC Buldukoglu [email protected] orcid.org/0000-0003-4230-1015 Department of Gastroenterology, Antalya Training and Research Hospital, University of Health Sciences, Antalya, TurkeySearch for more papers by this authorS Ocal, S Ocal Department of Gastroenterology, Antalya Training and Research Hospital, University of Health Sciences, Antalya, TurkeySearch for more papers by this authorAH Cekin, AH Cekin Department of Gastroenterology, Antalya Training and Research Hospital, University of Health Sciences, Antalya, TurkeySearch for more papers by this author OC Buldukoglu, Corresponding Author OC Buldukoglu [email protected] orcid.org/0000-0003-4230-1015 Department of Gastroenterology, Antalya Training and Research Hospital, University of Health Sciences, Antalya, TurkeySearch for more papers by this authorS Ocal, S Ocal Department of Gastroenterology, Antalya Training and Research Hospital, University of Health Sciences, Antalya, TurkeySearch for more papers by this authorAH Cekin, AH Cekin Department of Gastroenterology, Antalya Training and Research Hospital, University of Health Sciences, Antalya, TurkeySearch for more papers by this author First published: 07 March 2024 https://doi.org/10.1111/jgh.16535Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Koop AH, Travers PM, Khanna S, Pardi DS, Farraye FA, Hashash JG. Fidaxomicin treatment for Clostridioides difficile infection in patients with inflammatory bowel disease. J Gastroenterol Hepatol 2023; 38: 1910–1916. 10.1111/jgh.16265 CASPubMedWeb of Science®Google Scholar 2Alhobayb T, Ciorba MA. Clostridium difficile in inflammatory bowel disease. Curr Opin Gastroenterol 2023; 39: 257–262. 10.1097/MOG.0000000000000949 CASPubMedWeb of Science®Google Scholar 3Cornely OA, Crook DW, Esposito R et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12: 281–289. 10.1016/S1473-3099(11)70374-7 CASPubMedWeb of Science®Google Scholar 4Oksi J, Anttila VJ, Mattila E. Treatment of Clostridioides (Clostridium) difficile infection. Ann Med 2020; 52: 12–20. 10.1080/07853890.2019.1701703 PubMedWeb of Science®Google Scholar 5Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422–431. 10.1056/NEJMoa0910812 CASPubMedWeb of Science®Google Scholar 6Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 2012; 55: S121–S126. 10.1093/cid/cis440 CASPubMedWeb of Science®Google Scholar 7Peng Z, Jin D, Kim HB et al. Update on antimicrobial resistance in Clostridium difficile: resistance mechanisms and antimicrobial susceptibility testing. J Clin Microbiol 2017; 55: 1998–2008. 10.1128/JCM.02250-16 CASPubMedWeb of Science®Google Scholar 8Mullane KM, Miller MA, Weiss K et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53: 440–447. 10.1093/cid/cir404 CASPubMedWeb of Science®Google Scholar 9You JHS, Jiang X, Lee WH, Chan PKS, Ng SC. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease. J Gastroenterol Hepatol 2020; 35: 1515–1523. 10.1111/jgh.15002 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation